Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Paclitaxel 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cisplatin 2Carboplatin 2Bortezomib 2vandetanib 1umbralisib 1ublituximab 1regorafenib 1pomalidomide 1pembrolizumab 1nilotinib 1marizomib 1lutetium Lu 177 dotatate 1grapiprant 1fludarabine phosphate 1fludarabine 1durvalumab 1cemiplimab 1carotuximab 1axicabtagene ciloleucel 1avelumab 1Thioctic Acid 1Tamoxifen 1Receptors, Interleukin-6 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease Progression × grapiprant × Clear all
NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

University of Maryland, Baltimore

Phase 2 Withdrawn
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡